Simufilam

Simufilam (PTI-125) is an oral small-molecule drug candidate of the triazaspirodecanone structural class, developed by Cassava Sciences, Inc. for the treatment of mild-to-moderate Alzheimer's disease (AD). The compound's proposed mechanism centers on binding an altered conformation of the intracellular scaffolding protein filamin A (FLNA) that is reportedly induced by amyloid beta 1-42 (Abeta42) in AD brain tissue. According to the published preclinical literature, simufilam binds altered FLNA with femtomolar affinity and restores its native conformation, thereby disrupting two pathogenic signaling cascades: Abeta42 signaling via the alpha-7 nicotinic acetylcholine receptor (alpha7nAChR) that hyperphosphorylates tau protein, and persistent activation of toll-like receptor 4 (TLR4) that drives neuroinflammation. The proposed mechanism, if validated, would represent a first-in-class approach targeting a protein conformational change rather than a conventional receptor or enzyme.

The preclinical and early clinical pharmacology of simufilam was developed almost entirely within the laboratory of Hoau-Yan Wang at the City University of New York (CUNY), in collaboration with Lindsay Burns, then chief science officer of Cassava Sciences. Published reports from this laboratory described femtomolar binding affinity for altered FLNA, picomolar efficacy in postmortem human brain tissue, and reduction of tau hyperphosphorylation, amyloid aggregation, and inflammatory cytokine release in intracerebroventricular Abeta42-infusion and triple-transgenic mouse models. A Phase 2a open-label study in 13 AD patients (100 mg in the published literature for 28 days) reported significant reductions in cerebrospinal fluid biomarkers of neurodegeneration and neuroinflammation. These results, published in the Journal of Prevention of Alzheimer's Disease in 2020, provided the basis for Phase 3 advancement. However, the Wang laboratory subsequently became the subject of data integrity investigations: a CUNY panel initially cited Wang for "egregious misconduct" across 20 papers (later reversed under a different evidentiary standard), a federal grand jury indicted Wang for fraud involving approximately 16 million dollars in NIH grants (charges later dropped), seven Wang papers have been retracted, and the Journal of Neuroscience issued expressions of concern for two foundational simufilam papers. In September 2024, the U.S. Securities and Exchange Commission charged Cassava Sciences with securities fraud, resulting in a 40 million dollar settlement and the resignation and barring of the chief executive officer and chief science officer. Independent replication of the proposed FLNA conformation-modulation mechanism has not been published by laboratories outside the Wang group.

Two large Phase 3 randomized, double-blind, placebo-controlled trials evaluated simufilam in mild-to-moderate AD. The ReThink-ALZ trial (n = 804, simufilam 100 mg in the published literature versus placebo for 52 weeks) found no significant difference on either co-primary endpoint: ADAS-Cog12 (least-squares mean difference negative 0.39, p = 0.431) or ADCS-ADL (difference 0.51, p = 0.403). The ReFocus-ALZ trial (n = 1,125, simufilam 50 mg or 100 mg in the published literature versus placebo for 76 weeks) similarly failed all co-primary, secondary, and exploratory biomarker endpoints. No significant changes in plasma p-tau217, neurofilament light chain, or glial fibrillary acidic protein were observed. Simufilam was well tolerated in both trials, with an adverse event profile similar to placebo. Cassava Sciences discontinued the AD program in November 2024. An independent cell-culture assessment published in 2026 found that simufilam produced no beneficial effects on amyloid processing, neurotrophic factors, or mitochondrial function in differentiated human neuronal cells, aligning with the clinical outcomes.

This monograph documents the chemistry, proposed molecular pharmacology, pharmacokinetics, preclinical pharmacology, the complete clinical evidence base including Phase 3 trial results, the data integrity controversies that accompanied development, sourcing and handling considerations, adverse event profile, and a comparative assessment of five Alzheimer's disease therapeutic candidates against simufilam. The compound is not approved by any regulatory authority for any indication. Investigators considering simufilam for research applications should weigh the absence of independent mechanism validation, the complete Phase 3 clinical failure, and the unresolved questions regarding the integrity of the foundational preclinical data.